Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-12-18
2007-12-18
Pak, John (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S867000
Reexamination Certificate
active
11336406
ABSTRACT:
The present invention is directed to the prevention, reversal and medical treatment of lower urinary tract dysfunction including bladder instability and other related diseases as described below including urinary flow problems, urgency and incontinence as a result of prostate hyperplasia (BPH) and to the prevention, reversal and medical treatment of irritable bowl syndrome (IBS) with special focus on the diarrhea-predominant and mixed diarrhea-constipation type IBS, both in human beings and animals.
REFERENCES:
patent: 3513171 (1970-05-01), Thiele et al.
patent: 3651081 (1972-03-01), Sturm et al.
patent: 4668684 (1987-05-01), Tibes et al.
patent: 5162346 (1992-11-01), Lobisch et al.
patent: 5284861 (1994-02-01), Lobisch et al.
patent: 5503845 (1996-04-01), Goede et al.
patent: 6034111 (2000-03-01), Pergande et al.
patent: 6034112 (2000-03-01), Pergande et al.
patent: 6124326 (2000-09-01), Pergande et al.
patent: 6348486 (2002-02-01), Argentieri et al.
patent: 6668684 (2003-12-01), Allen et al.
patent: 7160684 (2007-01-01), Argentieri et al.
patent: 2006/0252104 (2006-11-01), Argentieri et al.
patent: 3133519 (1982-06-01), None
patent: 3133519 (1982-06-01), None
patent: 36 04 575 (1986-08-01), None
patent: 0 539 153 (1993-04-01), None
patent: 0 595 311 (1994-05-01), None
patent: 0 615 754 (1994-09-01), None
patent: 0 716 602 (1996-06-01), None
patent: 0 912 177 (1999-05-01), None
patent: 1 072 260 (2001-01-01), None
patent: 1 326 597 (2003-07-01), None
patent: WO 00/59487 (2000-10-01), None
patent: WO 01/39760 (2001-06-01), None
patent: WO 02/00217 (2002-01-01), None
patent: WO-02/32419 (2002-04-01), None
Derwent abstract 1986-298525; abstracting DE 3545201 (1987).
Derwent abstract 2002-269313; abstracting DE 10048969 (2002).
Derwent abstract 2002-442382; abstracting DE 10255415 (2004).
Derwent abstract 2001-182859; abstracting EP 1242078 (2002).
Freeman, R.M. et al., “Overactive bladder,” Best Practice & Research Clinical Obsterics and Gynaecology, vol. 19(6), pp. 829-841 (2005).
Medline abstract 2004332451 (2004).
Snelling, N., “Does any treatment work for irritable bowel syndrome?” International Journal of Osteopathic Medicine, vol. 9, pp. 137-142 (2006).
Farthing, M.J.G., “Treatment options in irritable bowel syndrome,” Best Practice & Research Clinical Gasteroenterology, vol. 18(4), pp. 773-786 (2004).
Schroeder, et al —KCNQ4 Channel Activation by BMS-204352 and retigabine. (Neuropharmacology (2001).
International Preliminary Report on Patentability issued for PCT/EP2006/000814, Jun. 28, 2007.
Benham, et al.: Acetylcholine activates and inward current in single mammalian smooth muscle cells,Nature,vol. 316, pp. 345-347(1985).
Sims, et al.: Antagonistic Adrenergic-Muscarinic Regulation of M Current in Smooth Muscle Cells,Science,vol. 239, pp. 190-193 (1988).
Longhurst, et al.: Influence of gender and the oestrous cycle on in vitro contractile responses of the rat urinary bladder to cholinergic stimulation,British J. of Pharm.,131, pp. 177-184 (2000).
Abrams, Describing bladder storage function : overactive bladder syndrome and detrusor overactivity, Urology 62 (Suppl. 5B): 28-37, 2003.
Mertz, Irritable Bowel Syndrome, N,. Eng. J. Med., 349:22; Nov. 27, 2003.
Ford, Do not go gentle—urinary troubles for more than the ageing, Drug Discovery World Fall 2003.
Szelenyi et al., Putative site(s) and mechanisms(s) of action of flupirtine, a novel analgesic compound, Postgraduate Med. J. (1987) 63, 57-50.
Rupalla et al., Flupirtine protects neurons against excitotoxic or ischemic damage and inhibits the increase in cytosolic Ca2+concentration, European J. of Pharmacology 294 (1995) 469-473.
Kornhuber et al., Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+block via activation of voltage independent potassium channels, J. Neural Transm. (1999) 106: 857-867.
Wein, Pharmacological agents for the treatment of urinary incontinence due to overactive bladder, Exp. Opin. Invest. Drugs (2001) 10(1):65-83.
Dray, The rat urinary bladder, a novel preparation for the investigation of central opioid activity in vitro, J. of Parm. Methods 13, 157-165 (1985).
Friedel et al., Flupirtine, A review of its pharmacological properties, and therapeutic efficacy in pain states, Drugs 45(4): 548-569, 1993.
Swartz et al., Antiparkinsonian effect of flupirtine in monoamine-depleted rats, J. of Neural Transmission (Vienna, Austria:1996), 103 (5) 581-90. Abstract.
Swarz et al., N-methyl-D-aspartate and alpha 2-adrenergic mechanisms are involved in the depressant action of flupirtine in spinal reflexes in rats, European J. of Pharmacology, (Apr. 4, 1995) 276(3) 247-55. Abstract.
Jakovlev et al., General pharmacologic studies on the analgesic flupirtine, Arzneimittel-Forschung (1985) 35(1) 44-55. Abstract.
Otto et al., Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study, Neurology, (Mar. 9, 2004) 62/5 (714-718). Abstract.
W. Vahlensieck Die stationare urologische Rehabilitation bei interstitieller Cystitis, Urologe-Ausgabe A 2005, Germany, vol. 44. Jan. 1, 2005.
Bernoester Katrin
Draheim Regina
Kuss Hildegard
Rundfeldt Chris
Elbion AG
Fulbright & Jaworski L.L.P.
Pak John
LandOfFree
Use of the non-opiate analgesic drug flupirtine for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of the non-opiate analgesic drug flupirtine for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of the non-opiate analgesic drug flupirtine for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3876466